{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '13.2 Appendix 2: Tuberculosis Risk Questionnaire', 'The following questions are to be asked to every subject for evaluation of signs and', 'symptoms of tuberculosis (TB). Responses to each question must be documented on this', 'source document.', 'Question', 'Response', '1) Does the subject have a new diagnosis of TB disease?', 'Yes', 'No', '2) Has the subject been in close contact (i.e., sharing the same household', 'Yes', 'No', 'or other enclosed environment, such as a social gathering place,', 'workplace, or facility, for extended periods during the day) with an', 'individual with active TB since the last scheduled visit?', '3) Has the subject become an employee at a TB hospital, forensic medical', 'Yes', 'No', 'examiner, or morgue since the last scheduled visit?', '4) Has the subject started work or has the subject stayed in long-stay', 'Yes', 'No', 'institutions (e.g., homes for elderly or disabled, prisons, etc) since the last', 'scheduled visit?', '5) Does the subject reside in or is the subject frequently travelling to a TB', 'Yes', 'No', 'endemic region (as defined in Table 5)? (only applicable for subjects not', 'living in an endemic region)', 'Not applicable', '6) Has the subject been in frequent contact with underprivileged', 'Yes', 'No', 'populations (homeless people or other people needing social assistance)', 'since the last scheduled visit?', '7) Does the subject have a new cough lasting more than 14 days or a', 'Yes', 'No', 'change in a chronic cough?', '8) Does the subject have night sweats?', 'Yes', 'No', '9) Does the subject have a persistent fever?', 'Yes', 'No', '10) Does the subject have unintentional weight loss (more than 10% of', 'Yes', 'No', 'body weight) in the past 3 months?', '11) Does the subject appear malnourished?', 'Yes', 'No', '12) Has the subject had an abnormal chest X-ray since the last', 'Yes', 'No', 'evaluation?', \"Physician's signature:\", 'Amendment 2: 06 March 2019', '147', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Table 5', 'List of Endemic TB Countries (Incidence >50/100,000)', 'Country', 'Incidence', 'Country', 'Incidence', 'Country', 'Incidence', 'Afghanistan', '189 (167-212)', 'Greenland', '197 (173-223)', 'Nigeria', '322 (189-488)', 'Algeria', '78 (64-94)', 'Guatemala', '57 (51-64)', 'Northern', '61 (53-69)', 'Mariana Islands', 'Angola', '370 (240-529)', 'Guinea', '177 (156-199)', 'Pakistan', '270 (201-350)', 'Azerbaijan', '77 (68-86)', 'Guinea-Bissau', '369 (261-495)', 'Papua New', '417 (304-547)', 'Guinea', 'Bangladesh', '227 (200-256)', 'Guyana', '103 (91-116)', 'Peru', '120 (98-145)', 'Belarus', '58 (50-67)', 'Haiti', '200 (177-225)', 'Philippines', '288 (254-324)', 'Benin', '61 (50-74)', 'India', '167 (156-179)', 'Romania', '81 (71-91)', 'Bhutan', '164 (148-181)', 'Indonesia', '399 (274-546)', 'Russia', '84 (76-93)', 'Bolivia', '120 (106-135)', 'Ivory Coast', '165 (150-179)', 'Rwanda', '63 (54-72)', 'Botswana', '385 (361-410)', 'Kazakhstan', '99 (64-141)', 'Sao Tome and', '97 (85-109)', 'Principe', 'Brunei', '62 (54-70)', 'Kenya', '246 (240-252)', 'Senegal', '138 (122-154)', 'Burkina Faso', '54 (48-59)', 'Kiribati', '497 (406-597)', 'Sierra Leone', '310 (235-394)', 'Burundi', '126 (116-136)', 'Kyrgystan', '142 (126-160)', 'Solomon', '86 (71-102)', 'Islands', 'Cabo Verde', '138 (122-156)', 'Laos', '189 (141-244)', 'Somalia', '274 (242-308)', 'Cambodia', '390 (353-428)', 'Lesotho', '852 (612-1130)', 'South Africa', '834 (737-936)', 'Cameroon', '220 (195-247)', 'Liberia', '308 (273-346)', 'South Korea', '86 (81-91)', 'Central African', '375 (333-420)', 'Lithuania', '62 (57-68)', 'South Sudan', '146 (121-173)', 'Republic', 'Chad', '159 (141-179)', 'Madagascar', '235 (207-264)', 'Sri Lanka', '65 (57-73)', 'China', '68 (63-73)', 'Malawi', '227 (122-365)', 'Sudan', '94 (52-148)', 'China, Hong', '74 (65-84)', 'Malaysia', '103 (83-124)', 'Swaziland', '733 (533-963)', 'Kong', 'China, Macao', '82 (72-93)', 'Mali', '58 (56-59)', 'Tanzania', '327 (155-561)', 'Congo', '381 (335-430)', 'Marshall Islands', '335 (274-402)', 'Tajikistan', '91 (80-103)', 'Democratic', '325 (295-356)', 'Mauritania', '111 (79-148)', 'Thailand', '171 (90-276)', 'Republic of', 'Amendment 2: 06 March 2019', '148', 'Confidential']\n\n###\n\n", "completion": "END"}